Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Debt to Equity (2016 - 2019)

Forte Biosciences (FBRX) has disclosed Debt to Equity for 4 consecutive years, with -$8.67 as the latest value for Q2 2019.

  • On a quarterly basis, Debt to Equity fell 1641.2% to -$8.67 in Q2 2019 year-over-year; TTM through Jun 2019 was -$8.67, a 1641.2% decrease, with the full-year FY2018 number at -$35.6, down 69905.83% from a year prior.
  • Debt to Equity was -$8.67 for Q2 2019 at Forte Biosciences, up from -$12.58 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.56 in Q2 2018 to a low of -$35.6 in Q4 2018.
  • A 4-year average of -$5.06 and a median of $0.03 in 2018 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 730.04% in 2018; the steepest drop was 69905.83% in 2018.
  • Forte Biosciences' Debt to Equity stood at -$0.08 in 2016, then surged by 161.96% to $0.05 in 2017, then tumbled by 69905.83% to -$35.6 in 2018, then surged by 75.66% to -$8.67 in 2019.
  • Per Business Quant, the three most recent readings for FBRX's Debt to Equity are -$8.67 (Q2 2019), -$12.58 (Q1 2019), and -$35.6 (Q4 2018).